A detailed history of Meiji Yasuda Life Insurance CO transactions in Incyte Corp stock. As of the latest transaction made, Meiji Yasuda Life Insurance CO holds 7,253 shares of INCY stock, worth $515,325. This represents 0.01% of its overall portfolio holdings.

Number of Shares
7,253
Previous 7,096 2.21%
Holding current value
$515,325
Previous $430,000 11.4%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$57.33 - $68.61 $9,000 - $10,771
157 Added 2.21%
7,253 $479,000
Q2 2024

Aug 12, 2024

SELL
$51.18 - $63.75 $113,107 - $140,887
-2,210 Reduced 23.75%
7,096 $430,000
Q1 2024

May 15, 2024

BUY
$56.55 - $66.59 $2,827 - $3,329
50 Added 0.54%
9,306 $530,000
Q4 2023

Feb 14, 2024

BUY
$52.16 - $64.19 $169,520 - $208,617
3,250 Added 54.11%
9,256 $581,000
Q2 2023

Aug 14, 2023

SELL
$60.95 - $75.51 $13,530 - $16,763
-222 Reduced 3.56%
6,006 $374,000
Q1 2023

May 10, 2023

BUY
$70.23 - $86.01 $21,841 - $26,749
311 Added 5.26%
6,228 $450,000
Q1 2022

May 17, 2022

BUY
$66.02 - $79.71 $17,957 - $21,681
272 Added 4.82%
5,917 $470,000
Q4 2020

Feb 12, 2021

SELL
$80.74 - $97.7 $70,324 - $85,096
-871 Reduced 13.37%
5,645 $491,000
Q3 2020

Nov 12, 2020

SELL
$85.07 - $109.69 $90,174 - $116,271
-1,060 Reduced 13.99%
6,516 $585,000
Q1 2020

May 14, 2020

BUY
$63.18 - $85.97 $478,651 - $651,308
7,576 New
7,576 $555,000
Q2 2019

Aug 14, 2019

SELL
$73.52 - $88.7 $279,376 - $337,060
-3,800 Closed
0 $0
Q1 2019

May 14, 2019

BUY
$63.56 - $88.17 $241,528 - $335,046
3,800 New
3,800 $327,000

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $15.8B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Meiji Yasuda Life Insurance CO Portfolio

Follow Meiji Yasuda Life Insurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Meiji Yasuda Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Meiji Yasuda Life Insurance CO with notifications on news.